BioWorld

July 24, 2003

View Archived Issues

Novartis, Cell Genesys Enter $28.5M Oncolytic Virus Deal

About five months after curtailing its gene therapy efforts in favor of other programs, Cell Genesys Inc.'s move has paid off in the form of a $28.5 million deal with Novartis AG to develop oncolytic virus products. (BioWorld Today) Read More

Micrologix Takes Hit On Failed Phase III Blood Infection Trial

Read More

Disrupted Hox Fetal Mouse Genes Implicated In Global Patterning Of Appendicular Skeleton Formation

Read More

Amgen Beats Earnings Forecast, Increases Full-Year EPS Guidance

Read More

Other News To Note

Read More

Appointments And Advancements

Read More